ProQR Therapeutics (PRQR) Competitors $2.79 +0.07 (+2.57%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRQR vs. COLL, PHAR, BCAX, RAPP, CRON, PGEN, XNCR, OCS, ORKA, and BGMShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Collegium Pharmaceutical (COLL), Pharming Group (PHAR), Bicara Therapeutics (BCAX), Rapport Therapeutics (RAPP), Cronos Group (CRON), Precigen (PGEN), Xencor (XNCR), Oculis (OCS), Oruka Therapeutics (ORKA), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Its Competitors Collegium Pharmaceutical Pharming Group Bicara Therapeutics Rapport Therapeutics Cronos Group Precigen Xencor Oculis Oruka Therapeutics BGM Group ProQR Therapeutics (NASDAQ:PRQR) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk. Is PRQR or COLL more profitable? Collegium Pharmaceutical has a net margin of 5.13% compared to ProQR Therapeutics' net margin of -238.52%. Collegium Pharmaceutical's return on equity of 97.28% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-238.52% -61.25% -28.13% Collegium Pharmaceutical 5.13%97.28%13.87% Does the media favor PRQR or COLL? In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 5 articles in the media. Collegium Pharmaceutical's average media sentiment score of 0.97 beat ProQR Therapeutics' score of -0.13 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Collegium Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, PRQR or COLL? ProQR Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Do insiders and institutionals believe in PRQR or COLL? 32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 2.5% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, PRQR or COLL? Collegium Pharmaceutical has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$20.46M14.35-$30.04M-$0.46-6.07Collegium Pharmaceutical$631.45M1.79$69.19M$1.0434.48 Do analysts recommend PRQR or COLL? ProQR Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 186.74%. Collegium Pharmaceutical has a consensus price target of $42.33, indicating a potential upside of 18.05%. Given ProQR Therapeutics' higher possible upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 2 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.70Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00 SummaryCollegium Pharmaceutical beats ProQR Therapeutics on 11 of the 16 factors compared between the two stocks. Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$293.54M$3.43B$6.17B$10.63BDividend YieldN/A2.24%5.72%4.86%P/E Ratio-6.0723.2329.5828.04Price / Sales14.35469.60572.92128.21Price / CashN/A45.5937.1261.42Price / Book3.0710.3012.016.50Net Income-$30.04M-$52.53M$3.33B$276.73M7 Day Performance-0.36%-0.07%-0.41%-0.21%1 Month Performance29.17%10.93%5.79%1.39%1 Year Performance-20.06%14.47%65.67%32.88% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.2705 of 5 stars$2.79+2.6%$8.00+186.7%-28.0%$293.54M$20.46M-6.07180COLLCollegium Pharmaceutical3.7601 of 5 stars$32.04flat$42.33+32.1%-1.3%$1.01B$631.45M30.81210News CoveragePHARPharming Group2.7583 of 5 stars$14.61+2.4%$30.00+105.3%+46.6%$977.71M$297.20M-112.38280Gap UpBCAXBicara Therapeutics2.6765 of 5 stars$18.51+4.1%$31.86+72.1%-27.4%$971.01MN/A-5.8432RAPPRapport Therapeutics3.0004 of 5 stars$26.19-1.2%$35.33+34.9%-1.3%$967.20MN/A-10.48N/ACRONCronos Group1.4028 of 5 stars$2.55+1.6%N/A+5.2%$961.06M$117.61M51.00450Positive NewsPGENPrecigen4.3424 of 5 stars$3.21+2.9%$8.25+157.0%+317.2%$929.68M$3.92M-7.64190Gap UpXNCRXencor3.7866 of 5 stars$13.96+7.1%$24.22+73.5%-37.4%$929.34M$110.49M-5.82280OCSOculis2.4073 of 5 stars$21.00-0.4%$41.00+95.2%+34.1%$920.84M$780K-7.872Short Interest ↑ORKAOruka Therapeutics2.8442 of 5 stars$25.50+4.1%$41.80+63.9%-11.7%$917.17MN/A-9.07N/ABGMBGM Group0.5299 of 5 stars$9.49+1.7%N/A+22.1%$907.08M$25.10M0.00298News CoverageShort Interest ↑Gap Up Related Companies and Tools Related Companies Collegium Pharmaceutical Competitors Pharming Group Competitors Bicara Therapeutics Competitors Rapport Therapeutics Competitors Cronos Group Competitors Precigen Competitors Xencor Competitors Oculis Competitors Oruka Therapeutics Competitors BGM Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
